{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:32Z","timestamp":1791272372072,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,19]],"date-time":"2020-01-19T00:00:00Z","timestamp":1579392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neuroendocrine tumors (NETs) throughout the body are the focus of much current interest. Most occur in the gastrointestinal tract and have shown a major increase in incidence over the past 30 years, roughly paralleling the world-wide increase in the use of proton pump inhibitor (PPI) drugs. The greatest rise has occurred in gastric carcinoids (g-NETs) arising from enterochromaffin-like (ECL) cells. These tumors are long known to occur in auto-immune chronic atrophic gastritis (CAG) and Zollinger-Ellison syndrome (ZES), with or without multiple endocrine neoplasia type-1 (MEN-1), but the incidences of these conditions do not appear to have increased over the same time period. Common to these disease states is persistent hypergastrinemia, generally accepted as causing g-NETs in CAG and ZES, and postulated as having similar tumorigenic effects in PPI users. In efforts to study the increase in their occurrence, g-NETs have been classified in a number of discussed ways into different grades that differ in their incidence and apparent pathogenesis. Based on a large amount of experimental data, tumorigenesis is mediated by gastrin\u2019s effects on the CCK2R-receptor on ECL-cells that in turn leads to hyperplasia, dysplasia, and finally neoplasia. However, in all three conditions, the extent of response of ECL-cells to gastrin is modified by a number of genetic influences and other underlying risk factors, and by the duration of exposure to the hormonal influence. Data relating to trophic effects of hypergastrinemia due to PPI use in humans are reviewed and, in an attached Appendix A, all 11 reports of g-NETs that occurred in long-term PPI users in the absence of CAG or ZES are summarized. Mention of additional suspected cases reported elsewhere are also listed. Furthermore, the risk in humans may be affected by the presence of underlying conditions or genetic factors, including their PPI-metabolizer phenotype, with slow metabolizers likely at increased risk. Other problems in estimating the true incidence of g-NETs are discussed, relating to non-reporting of small tumors and failure of the Surveillance, Epidemiology, and End Results Program (SEER) and other databases, to capture small tumors or those not accorded a T1 rating. Overall, it appears likely that the true incidence of g-NETs may be seriously underestimated: the possibility that hypergastrinemia also affects tumorigenesis in additional gastrointestinal sites or in tumors in other organ systems is briefly examined. Overall, the risk of developing a g-NET appears greatest in patients who are more than 10 years on drug and on higher doses: those affected by chronic H. pylori gastritis and\/or consequent gastric atrophy may also be at increased risk. While the overall risk of g-NETs induced by PPI therapy is undoubtedly low, it is real: this necessitates caution in using PPI therapy for long periods of time, particularly when initiated in young subjects.<\/jats:p>","DOI":"10.3390\/ijms21020662","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T04:27:09Z","timestamp":1579494429000},"page":"662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids\u2014What Is the Relationship?"],"prefix":"10.3390","volume":"21","author":[{"given":"Denis M.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Departments of Medicine &amp;  Biochemistry, Division of Gastroenterology and Hepatology, University of New Mexico School of Medicine and Raymond G. Murphy Veterans Administration Medical Center, 1501 San Pedro Blvd. SE, Albuquerque, NM 87108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/01.pas.0000213326.86992.98","article-title":"Sporadic duodenal bulb gastrin-cell tumors: Association with Helicobacter pylori gastritis and Long-term use of proton pump inhibitors","volume":"30","author":"Merchant","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2017.08.038","article-title":"Gastrin induces nuclear export and proteasome degradation of Menin in enteric glial cells","volume":"153","author":"Sunderasan","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/17.5.303","article-title":"The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept","volume":"17","author":"Pearse","year":"1969","journal-title":"J. Histochem. Cytochem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence and survival outcomes in patients with Neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/ajg.2010.341","article-title":"Carcinoid tumors in the gastrointestinal tract: Trends in incidence in England since 1971","volume":"105","author":"Ellis","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinak carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1055\/s-0030-1255564","article-title":"Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: Small tumors, small problems?","volume":"42","author":"Scherubl","year":"2010","journal-title":"Endoscopy"},{"key":"ref_8","unstructured":"Feldman, L.S., and Brandt, L.J. (2016). Neuroendocrine Tumors. Sleisenger and Fordtran\u2019s Textbook of Gastroenterology and Liver Disease, Elsevier. [10th ed.]."},{"key":"ref_9","unstructured":"Rimdi, G., Arnold, R., Bosman, F.T., Capella, C., and Bosman, F.T. (2010). WHO Classification of Tumours of the Digestive System, IARC Press."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well differentiated neuroendocrine tumors with a morphologically high grade component: A pathway distinct from poorly differentiated neuroendocrine carcinoma","volume":"22","author":"Tang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, L., Ramos-Alvarez, I., Ito, T., and Jensen, R.T. (2019). Insights into effects\/risks of chronic hypergastrinemia and lifelong PPI treatment in man based on studies of patients with Zollinger-Ellison Syndrome. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205128"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10620-015-4014-0","article-title":"Solitary gastric carcinoid associated with longterm use of omeprazole: A case report and review of the literature","volume":"61","author":"Nandy","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.gtc.2013.01.009","article-title":"Gastric Carcinoids (Neuroendocrine Neoplasms)","volume":"42","author":"Kidd","year":"2013","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/apt.12090","article-title":"Treatment of gastric carcinoid type-1with the gastrin receptor antagonist netazeoide (YF476) results in regression of tumors and normalization of serum chromogranin A","volume":"36","author":"Fossmark","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.12135","article-title":"Commentary: A gastrin antagonist against carcinoids - implications for PPI-induced hypergastrinemia","volume":"37","author":"McCarthy","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fendo.2019.00339","article-title":"Multiple Endocrine Neoplasia Type 1 (MEN-1): An update and the significance of early genetic and clinical diagnosis","volume":"10","author":"Crystal","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G752","DOI":"10.1152\/ajpgi.00109.2012","article-title":"Conditional deletion of Menin results in antral G-cell hyperplasia and hypergastrinemia","volume":"303","author":"Veniaminova","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/gut.2006.108910","article-title":"Allelic deletion of the MEN 1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions","volume":"56","author":"Anlauf","year":"2016","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00268-004-7345-0","article-title":"Regression of type11 gastric carcinoids in Multiple Endocrine Neoplasia Type1patients with Zollinger-Ellison Syndrome after surgical excision of all gastrinomas","volume":"28","author":"Richards","year":"2004","journal-title":"World J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00535-004-1354-5","article-title":"Reg Protein is a unique growth factor of gastric mucosal cells","volume":"39","author":"Kinoshita","year":"2004","journal-title":"J. Gastronterol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Waldum, H.L., Sordal, O.F., and Mjones, P.G. (2019). The enterochromaffin-like [ECL] cell\u2014Central in Gastric physiology and pathology. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102444"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fossmark, R., Martinsen, T.C., and Waldum, H.L. (2019). Adverse effects of proton pump inhibitors\u2014Evidence and plausibility. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205203"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1093\/hmg\/ddv054","article-title":"Exome sequencing identifies ATP4A gene as responsible for an atypical familial type 1 gastric neuroendocrine tumor","volume":"24","author":"Calvete","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/apm.12546","article-title":"ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPASE alpha subunit","volume":"124","author":"Fossmark","year":"2016","journal-title":"APMIS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02739887","article-title":"An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal hypertrophy","volume":"6","author":"Ooji","year":"1995","journal-title":"Endocr. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000484688","article-title":"Hypergastrinemia in long-term use of proton pump inhibitors","volume":"97","author":"Shiotani","year":"2018","journal-title":"Digestion"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dld.2013.09.021","article-title":"The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin","volume":"46","author":"Helgadottir","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-201x.2000.00688.x","article-title":"Gastrin has a specific proliferative effect on the rat entrochromaffin-like cell, but not on the parietal cell: A study by elutriation centrifugation","volume":"169","author":"Bakke","year":"2000","journal-title":"Acta Physiol. Scand."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/gut.33.10.1303","article-title":"Trophic Effect of gastrin on the enterochromaffin like cells of the rat stomach: Establishment of a dose response relationship","volume":"33","author":"Brenna","year":"1992","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic Review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","first-page":"330","article-title":"Gastric carcinoid tumors: The biology and therapy of an enigmatic and controversial lesion","volume":"90","author":"Gilligan","year":"1995","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MED.0000000000000215","article-title":"Chromogranin A: Any relevance in neuroendocrine tumors?","volume":"23","author":"Kidd","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5001\/omj.2017.71","article-title":"Chromogranin A as a biomedical marker for neuroendocrine tumors: A single center experience at Royal Hospital, Oman","volume":"32","year":"2017","journal-title":"Oman Med. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1018881617038","article-title":"Human Gastric carcinoid detected during long-term anti-ulcer therapy of H2 receptor antagonist and proton pump inhibitor","volume":"43","author":"Haga","year":"1998","journal-title":"Dig Dis Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0140-6736(05)71964-4","article-title":"Omeprazole in esophageal reflux disease","volume":"356","author":"Dawson","year":"2000","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10620-005-2466-3","article-title":"Multifocal gastric carcinoid tumor in patient with pernicious anemia receiving Lansoprazole","volume":"50","author":"Attila","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/00365521.2011.627444","article-title":"Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor","volume":"47","author":"Jianu","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","article-title":"Gastric carcinoids after long-term use of a proton pump inhibitor","volume":"36","author":"Jianu","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/00365521.2013.878381","article-title":"Gastric carcinoid in the absence of atrophic body gastritis and with low Ki-67 index: A clinical challenge","volume":"49","author":"Lahner","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3109\/00365521.2015.1054426","article-title":"Gastric neuroendocrine neoplasms and proton pump inhibitors: Fact orco-incidence?","volume":"50","author":"Cavalcoli","year":"2014","journal-title":"Scand. J. Gastroerol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1590-8658(01)80050-5","article-title":"Changes in Gastric mucosa and luminal environment during acid-suppressive therapy: A review in depth","volume":"33","author":"Sanduleanu","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/gut.2005.090514","article-title":"Proton Pump Inhibitors and gastric neoplasia","volume":"55","author":"Kuipers","year":"2006","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ma, C., Shaheen, A.A., Congley, S.E., and Andrews, C.N. (2019). Interpreting reported risks associated with use of proton pump inhibitors: Residual confounding in a 10-year analysis of national ambulatory data. Gastroenterology.","DOI":"10.1053\/j.gastro.2019.10.023"},{"key":"ref_45","unstructured":"Food and Drug Administration (2000, January 20). Hypergastrinemia, ECL-cell Hyperplasia and Atrophic Gastritis. FDA Background. Omeprazole magnesium (Prilosec TM) Astra Zeneca with Proctor and Gamble. Proceedings of the Non-Prescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee, Gaithersburg, MD, USA. Available online: https:\/\/wayback.archive-it.org\/7993\/20170403184623\/https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00mtbc.htm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00464-005-0232-4","article-title":"Gastric Carcinoids","volume":"19","author":"Hodgson","year":"2005","journal-title":"Surg. Endosc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","article-title":"Updated population-based review of carcinoid tumors","volume":"240","author":"Maggard","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Waldum, H.L., Oberg, K., Sandvik, A.K., and Gustafsson, B.I. (2018). Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumors: Time for a paradigm shift. Ther. Adv. Gastroenterol.","DOI":"10.1177\/1756284818775054"},{"key":"ref_50","first-page":"1","article-title":"long-term use of proton pump inhibitors and risk of gastric cancer: A review of the current evidence","volume":"2","author":"Cheung","year":"2019","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1080\/00365521.2019.1663446","article-title":"Gastric cancer and gastrin: On the interaction of Helicobacter gastritis and acid-inhibitory induced hypergastrinemia","volume":"54","author":"Waldum","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cgh.2016.05.018","article-title":"Use of proton pump inhibitors and risk of fundic gland polyps and gastric cancer: Systematic review and meta-analysis","volume":"14","author":"Spaetgens","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Brusselaers, N., Wahlin, K., Engstrand, L., and Lagergren, J. (2017). Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open, e017739.","DOI":"10.1136\/bmjopen-2017-017739"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:29:51Z","timestamp":1760362191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,19]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijms21020662"],"URL":"https:\/\/doi.org\/10.3390\/ijms21020662","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,19]]}}}